Peter R. Galle
Impact in
- Hepatology top 0.01%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Liver Disease and Transplantation
- Immunology top 0.05%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
- Hepatology 317
- Hepatocellular Carcinoma Treatment and Prognosis 155
- Liver Disease and Transplantation 62
- Hepatitis C virus research 60
- Oncology 232
- Colorectal Cancer Treatments and Studies 54
- Pancreatic and Hepatic Oncology Research 39
- Co-authors
- Markus F. Neurath (116 shared papers)Vincenzo Mazzaferro (6 shared papers)Josep M. Llovet (36 shared papers)Alejandro Forner (2 shared papers)Jean‐Luc Raoul (5 shared papers)Peter Schirmacher (14 shared papers)Fabio Piscaglia (4 shared papers)Valérie Vilgrain (1 shared paper)
- Journals
- Journal of Hepatology (66 papers)Journal of Clinical Oncology (56 papers)Gastrointestinal Endoscopy (30 papers)Gastroenterology (28 papers)Annals of Oncology (27 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Peter R. Galle
1.1k papers receiving 55.3k citations
Peter R. Galle's Hit Papers
Peers
Comparison fields: 5 of 211
- Hepatology 17.7k
- Immunology 9.0k
- Oncology 10.4k
- Epidemiology 11.3k
- Cancer Research 4.5k
Countries citing papers authored by Peter R. Galle
This map shows the geographic impact of Peter R. Galle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. Galle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. Galle more than expected).
Fields of papers citing papers by Peter R. Galle
This network shows the impact of papers produced by Peter R. Galle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. Galle. The network helps show where Peter R. Galle may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter R. Galle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.1k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma Hit paper breakdown → | 2018 | 7087 |
| 2 | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update Hit paper breakdown → | 2021 | 2546 |
| 3 | Simplified criteria for the diagnosis of autoimmune hepatitis† Hit paper breakdown → | 2008 | 1289 |
| 4 | Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma Hit paper breakdown → | 2014 | 1099 |
| 5 | Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 Hit paper breakdown → | 2004 | 970 |
| 6 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 967 |
| 7 | Colorectal cancer Hit paper breakdown → | 2005 | 936 |
| 8 | Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? Hit paper breakdown → | 1996 | 810 |
| 9 | p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs Hit paper breakdown → | 1998 | 739 |
| 10 | Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Hit paper breakdown → | 1997 | 677 |
| 11 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Hit paper breakdown → | 2012 | 675 |
| 12 | CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes Hit paper breakdown → | 2003 | 660 |
| 13 | Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo Hit paper breakdown → | 2004 | 639 |
| 14 | Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis Hit paper breakdown → | 2003 | 634 |
| 15 | TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling Hit paper breakdown → | 2004 | 624 |
| 16 | Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. Hit paper breakdown → | 1995 | 609 |
| 17 | p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Hit paper breakdown → | 1995 | 600 |
| 18 | The Transcription Factor T-bet Regulates Mucosal T Cell Activation in Experimental Colitis and Crohn's Disease Hit paper breakdown → | 2002 | 520 |
| 19 | Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet Hit paper breakdown → | 2002 | 514 |
| 20 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions Hit paper breakdown → | 2013 | 507 |
About Peter R. Galle
Peter R. Galle is a scholar working on Hepatology, Oncology, Epidemiology, Surgery and Pulmonary and Respiratory Medicine, having authored 1.1k papers that have together received 56.8k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (155 papers), Liver Disease Diagnosis and Treatment (111 papers), Hepatitis B Virus Studies (65 papers), Liver Disease and Transplantation (62 papers), Hepatitis C virus research (60 papers), Gastric Cancer Management and Outcomes (57 papers), Colorectal Cancer Treatments and Studies (54 papers) and Pancreatic and Hepatic Oncology Research (39 papers). The work is most often cited by research in Hepatology (17.7k citations), Immunology (9.0k citations), Oncology (10.4k citations), Epidemiology (11.3k citations) and Cancer Research (4.5k citations). Peter R. Galle has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Markus F. Neurath, Vincenzo Mazzaferro, Josep M. Llovet, Alejandro Forner, Jean‐Luc Raoul, Peter Schirmacher, Fabio Piscaglia, Valérie Vilgrain, Ralf Kießlich and Wolfgang Stremmel. Their work appears in journals such as Journal of Hepatology, Journal of Clinical Oncology, Gastrointestinal Endoscopy, Gastroenterology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.